Reports
Sale
Global Viral Inactivation Market Size, Trends, Analysis, Forecast: By Product: Kits and Reagents, Services, Viral Inactivation Systems and Accessories; By Application: Vaccines and Therapeutics, Stem Cell Products, Blood and Blood Products, Tissue and Tissue Products, Others; By End User; Regional Analysis; Supplier Landscape; 2023-2031
Global Viral Inactivation Market Outlook
The global viral inactivation market size was valued at USD 615.8 million in 2022, driven by rising prevalence of chronic diseases such as cancer, autoimmune disorders, and other diseases, and rising healthcare expenditures. The market is estimated to grow at a CAGR of 11.5% during the forecast period 2023-2031 to attain a value of USD 1640.3 million by 2031.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America to be a Significant Regional Market for Viral Inactivation
North America is expected to account for a considerable share of the viral inactivation industry. This can be attributed to the robust healthcare infrastructure, and the presence of large pharmaceutical and biopharmaceutical companies. The increasing healthcare research and development (R&D) spending by the United States government is expected to fuel the market in North America. The robust growth of the pharmaceuticals industry, the surging approvals of novel drugs, and the rising penetration of research and academic institutes that promote biotechnology and life science research activities are projected to boost the growth of the viral inactivation industry. Moreover, the increasing use of technologically advanced processes for the production of new and novel drugs is anticipated to bolster the market for viral inactivation in the forecast period.
The viral inactivation industry in Europe is witnessing robust growth due to the increasing spending on research and development (R&D) activities and new product releases in the life sciences industry. Meanwhile, due to the expanding healthcare infrastructure, the Asia Pacific region is predicted to grow rapidly. The increasing prevalence of chronic diseases in developing economies like India and China and the growing interests in life sciences and biotechnology research activities are estimated to invigorate the viral inactivation industry in the coming years.
Viral Inactivation: Market Segmentation
Viral inactivation is a method of viral elimination in which the viruses are removed but remain non-infectious in the finished product. The inactivation of viruses is a crucial step in the viral clearance process. Viral inactivation is integral in the manufacturing of biological goods such as tissue and tissue products, stem cell products, vaccines and medicines, among others.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By product, the market is divided into:
- Kits and Reagents
- Systems
- Services
The significant applications of viral inactivation are:
- Vaccines and Therapeutics
- Stem Cell Products
- Blood and Blood Products
- Tissue and Tissue Products
- Cellular and Gene Therapy
The various end-uses of viral inactivation in the market are:
- Pharmaceutical and Biotechnology Companies
- CROs
- Academic and Research Institutes
- Others
The EMR report looks into the regional markets of viral inactivation like into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Prevalence of Chronic Diseases to Augment the Market Growth of Viral Inactivation
The rising prevalence of chronic diseases such as cancer, autoimmune disorders, and other diseases, and rising healthcare expenditures are driving the viral inactivation industry. The market is also being propelled by the rapid growth of the pharmaceutical and biotechnology industries, and the increasing launches of novel medication. Various governments are increasingly introducing favourable initiatives to support and fund viral inactivation research activities to prevent viral outbreaks, especially in the wake of the COVID-19 pandemic. With the growing concerns regarding the transmission of blood-borne viruses through plasma-derived medical goods, the demand for effective viral inactivation is significantly surging and driving the market growth.
The increasing investments in research and development (R&D) activities for the development of innovative therapeutics in the life science industry is leading to a surge in the use of kits and reagents, which is invigorating the market growth. Advancements in nano filtration technology are surging the demand for viral inactivation for efficient viral elimination in the manufacturing of biopharmaceutical drugs, therefore adding to the market growth. Furthermore, the increased research and development (R&D) activities for innovations in stem cell and cellular and gene therapy are expected to provide lucrative growth opportunities for the market expansion in the forecast period.
Key Industry Players in the Global Viral Inactivation Market
The report gives a detailed analysis of the following key players in the global viral inactivation market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Rad Source Technologies Inc
- Merck KGaA
- Parker Hannifin Corp
- Sartorius AG
- Cerus Corporation
- Cytiva (Danaher Corporation)
- Charles River Laboratories
- CONVATEC GROUP PLC
- WuXi AppTec
- TERUMO BCT, INC.
- Thermo Fisher Scientific Inc.
- SCI Automation
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Application |
|
| Breakup by End-user |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Viral Inactivation Market Overview
3.1 Global Viral Inactivation Market Historical Value (2016-2022)
3.2 Global Viral Inactivation Market Forecast Value (2023-2031)
4 Global Viral Inactivation Market Landscape
4.1 Global Viral Inactivation Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Viral Inactivation Product Landscape
4.2.1 Analysis by Product
4.2.2 Analysis by Application
4.2.3 Analysis by End User
5 Global Viral Inactivation Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Viral Inactivation Market Segmentation
6.1 Global Viral Inactivation Market by Product
6.1.1 Market Overview
6.1.2 Kits and Reagents
6.1.3 Services
6.1.4 Viral Inactivation Systems and Accessories
6.2 Global Viral Inactivation Market by Application
6.2.1 Market Overview
6.2.2 Vaccines and Therapeutics
6.2.3 Stem Cell Products
6.2.4 Blood and Blood Products
6.2.5 Tissue and Tissue Products
6.2.6 Cellular and Gene Therapy
6.3 Global Viral Inactivation Market by End User
6.3.1 Market Overview
6.3.2 Pharmaceutical and Biotechnology Companies
6.3.3 CROs
6.3.4 Academic and Research Institutes
6.3.5 Others
6.4 Global Viral Inactivation Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Viral Inactivation Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Viral Inactivation Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Viral Inactivation Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Viral Inactivation Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Viral Inactivation Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Rad Source Technologies Inc
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Merck KGaA
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Parker Hannifin Corp
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Sartorius AG
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Cerus Corporation
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Cytiva (Danaher Corporation)
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Charles River Laboratories
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 CONVATEC GROUP PLC
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 WuXi AppTec
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 TERUMO BCT, INC.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Thermo Fisher Scientific Inc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 SCI Automation
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
18 Global Viral Inactivation Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The global market for viral inactivation reached a value of USD 615.8 million in 2022.
The market is anticipated to grow at a CAGR of 11.5% during the forecast period of 2023-2031 to reach a value of USD 1640.3 million by 2031.
The market is being driven by the increasing approvals of novel drugs, the surging use of technologically advanced processes in development of new drugs, and the robust growth of the healthcare industry.
The growing prevalence of chronic diseases, the rapid growth of the biotechnology and life sciences industry, and advancements in nano filtration technology are projected to propel the growth of the market.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The major products of viral inactivation are kits and reagents, systems, and services.
The significant applications of viral inactivation in the market are vaccines and therapeutics, stem cell products, blood and blood products, tissue and tissue products, and cellular and gene therapy.
The various end-uses in the market are pharmaceutical and biotechnology companies, CROs, and academic and research institutes, among others.
The major players in the industry are Rad Source Technologies Inc, Merck KGaA, Parker Hannifin Corp, Sartorius AG, Cerus Corporation, Cytiva (Danaher Corporation), Charles River Laboratories, CONVATEC GROUP PLC, WuXi AppTec, TERUMO BCT, INC., Thermo Fisher Scientific Inc., and SCI Automation, among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999$2999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999$5999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER